Lofland J - Search Results

1

Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream.

Smith P, Yao W, Shepard S, Covington M, Lee J, Lofland J, Naim A, Sheth T, Parikh B, Yeleswaram S. Smith P, et al. Among authors: lofland j. Pharmaceutics. 2021 Jul 8;13(7):1044. doi: 10.3390/pharmaceutics13071044. Pharmaceutics. 2021. PMID: 34371735 Free PMC article. Review.

2

The Employee Absenteeism Costs of Rheumatoid Arthritis: Evidence From US National Survey Data.

Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Naim A, Lofland JH. Gunnarsson C, et al. Among authors: lofland jh. J Occup Environ Med. 2015 Jun;57(6):635-42. doi: 10.1097/JOM.0000000000000461. J Occup Environ Med. 2015. PMID: 26053366

3

Novel Statistical Approach to Determine Inflammatory Bowel Disease: Patients' Perspectives on Shared Decision Making.

Siegel CA, Lofland JH, Naim A, Gollins J, Walls DM, Rudder LE, Reynolds C. Siegel CA, et al. Among authors: lofland jh. Patient. 2016 Feb;9(1):79-89. doi: 10.1007/s40271-015-0126-z. Patient. 2016. PMID: 25963447

4

Adjusting for comorbidities in cost of illness studies.

Rizzo JA, Chen J, Gunnarsson CL, Naim A, Lofland JH. Rizzo JA, et al. Among authors: lofland jh. J Med Econ. 2015 Jan;18(1):12-28. doi: 10.3111/13696998.2014.969434. Epub 2014 Oct 9. J Med Econ. 2015. PMID: 25253504 Free article.

5

Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III Studies.

Bloudek L, Eichenfield LF, Silverberg JI, Joish VN, Lofland JH, Sun K, Augustin M, Migliaccio-Walle K, Sullivan SD. Bloudek L, et al. Among authors: lofland jh. Am J Clin Dermatol. 2023 Jan;24(1):109-117. doi: 10.1007/s40257-022-00734-8. Epub 2022 Oct 20. Am J Clin Dermatol. 2023. PMID: 36264430 Free PMC article. Clinical Trial.

6

The direct healthcare insurer and out-of-pocket expenditures of psoriasis: evidence from a United States national survey.

Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Naim A, Lofland JH. Gunnarsson C, et al. Among authors: lofland jh. J Dermatolog Treat. 2012 Aug;23(4):240-54. doi: 10.3109/09546634.2010.550911. Epub 2011 Jul 31. J Dermatolog Treat. 2012. PMID: 21801089

7

The employee absenteeism costs of inflammatory bowel disease: evidence from US National Survey Data.

Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Naim A, Lofland JH. Gunnarsson C, et al. Among authors: lofland jh. J Occup Environ Med. 2013 Apr;55(4):393-401. doi: 10.1097/JOM.0b013e31827cba48. J Occup Environ Med. 2013. PMID: 23232289

8

Gastroenterologists' Views of Shared Decision Making for Patients with Inflammatory Bowel Disease.

Siegel CA, Lofland JH, Naim A, Gollins J, Walls DM, Rudder LE, Reynolds C. Siegel CA, et al. Among authors: lofland jh. Dig Dis Sci. 2015 Sep;60(9):2636-45. doi: 10.1007/s10620-015-3675-z. Epub 2015 May 5. Dig Dis Sci. 2015. PMID: 25939543 Free PMC article.

9

Direct health care insurer and out-of-pocket expenditures of inflammatory bowel disease: evidence from a US national survey.

Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Lofland JH. Gunnarsson C, et al. Among authors: lofland jh. Dig Dis Sci. 2012 Dec;57(12):3080-91. doi: 10.1007/s10620-012-2289-y. Epub 2012 Jul 12. Dig Dis Sci. 2012. PMID: 22790905

10

Cost-per-remission analysis of infliximab compared to adalimumab among adults with moderate-to-severe ulcerative colitis.

Lofland JH, Mallow P, Rizzo J. Lofland JH, et al. J Med Econ. 2013;16(4):461-7. doi: 10.3111/13696998.2013.775134. Epub 2013 Feb 27. J Med Econ. 2013. PMID: 23445401 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

50 results

Search Page